ROSEN, LEADING TRIAL ATTORNEYS, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Merck & Co., Inc. securities between February 3, 2022, and February 3, 2025, about the April 14, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Merck securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 14, 2025 [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]. Group 2: Case Background - The lawsuit alleges that throughout the Class Period, Merck provided misleading information regarding expected revenue of $11 billion from Gardasil sales by 2030, while concealing adverse facts about demand visibility in China [4]. - Defendants reportedly made overly optimistic statements about Gardasil's growth potential in China, despite lacking insight into actual demand among targeted populations, leading to inflated inventory levels [4].